Galectin-3 plasmapheresis therapy
AssigneeEliaz Therapeutics, Inc.
InventorIsaac Eliaz
Life of this patent
Estimating the term…
Abstract
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
Claims5
A method of maintaining homeostatic cellular health in a mammal as measured by at least one of cell adhesion, cell migration, cell invasion, angiogenesis and apoptosis, comprising withdrawing blood from said mammal, passing said blood past a galectin-3 binding molecule such that at least 10% of the level of active galectin-3 in the blood of said mammal is bound to said binding molecule, and returning said withdrawn blood to said mammal without said galectin-3 bound by said binding molecule.
Dependencies are inferred from the claim text.